Kaplan-Meier survival curves further demonstrated that disease-free survival (DFS) and OS were worse in GC patients with higher CXCL16 expression than in patients with lower CXCL16 expression, respectively (P=0.0499 and 0.0308, Fig. 1B and C). This evidence concerns the gene CXCL16 and gastric cancer.